Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Merkelbach Bruse, Sabine ^a   Dietmaier, Wolfgang ^b   Füzesi, Laszlo ^c   Gaumann, Andreas ^b   Haller, Florian ^c,h   Kitz, Julia ^c   Krohn, Antje ^d   Mechtersheimer, Gunhild ^e   Penzel, Roland ^e   Schildhaus, Hans Ulrich ^a   Schneider Stock, Regine ^f,g   Simon, Ronald ^d   Wardelmann, Eva ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KIT; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; EXON; FALSE POSITIVE RESULT; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LABORATORY; MUTATIONAL ANALYSIS; POINT MUTATION; WILD TYPE; DISEASE FREE SURVIVAL; GENETICS; GERMANY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EXONS; GASTROINTESTINAL STROMAL TUMORS; GERMANY; HUMANS; MUTATION; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 77954123084     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-106     Document Type: Article

References (30)

1. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom A, Blay J, Leyvraz S, Stul M, Casali P, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103. 10.1016/j.ejca.2006.01.030, 16624552.
2. Heinrich M, Owzar K, Corless C, Hollis D, Borden E, Fletcher C, Ryan C, von Mehren M, Blanke C, Rankin C, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008, 26:5360-5367. 10.1200/JCO.2008.17.4284, 2651078, 18955451.
3. Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus H. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007, 451:743-749. 10.1007/s00428-007-0473-9, 17701051.
4. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008, 53:245-266. 10.1111/j.1365-2559.2008.02977.x, 18312355.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83. 10.1053/j.semdp.2006.09.001, 17193820.
6. Corless C, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich M. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23:5357-5364. 10.1200/JCO.2005.14.068, 15928335.
7. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161:1961-1971. 1850907, 12466110.
8. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R, Merkelbach-Bruse S. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003, 106:887-895. 10.1002/ijc.11323, 12918066.
9. Martin J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero J, Garcia del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande J, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005, 23:6190-6198. 10.1200/JCO.2005.19.554, 16135486.
10. Antonescu C, Sommer G, Sarran L, Tschernyavsky S, Riedel E, Woodruff J, Robson M, Maki R, Brennan M, Ladanyi M, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003, 9:3329-3337.
11. Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R, Michal M, Boltze C, Roessner A, Stachura J, Miettinen M. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003, 34:1306-1312. 10.1016/S0046-8177(03)00407-6, 14691917.
12. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P, Losen I, Manegold C, Büttner R, Pietsch T. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004, 6:197-204. 1867629, 15269295.
13. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006, 86:94-100. 10.1038/labinvest.3700360, 16258521.
14. Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84:874-883. 10.1038/labinvest.3700122, 15146165.
15. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schöffski P, Marynen P, Debiec-Rychter M. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRA D842V mutation. Clin Cancer Res 2008, 14:5749-5758. 10.1158/1078-0432.CCR-08-0533, 18794084.
16. Demetri G, Benjamin R, Blanke CD, Blay J, Casali P, Choi H, Corless C, Debiec-Rychter M, DeMatteo R, Ettinger D, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007, 5:S1-S29.
17. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali P, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009, 35:739-745.
18. Von Mehren M. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Curr Opin Oncol 2008, 20:428-432. 10.1097/CCO.0b013e328302ed82, 18525339.
19. De Franchis R, Cross N, Foulkes N, Cox T. A potent inhibitor of Taq polymerase copurifies with human genomic DNA. Nucleic Acids Res 1988, 16:10355. 10.1093/nar/16.21.10355, 338857, 3194201.
20. Greer C, Wheeler C, Manos M. Sample preparation and PCR amplification from paraffin-embedded tissues. Meth Appl 1994, 3:113-122.
21. Dubeau L, Chandler L, Gralow J, Nichols P, Jones P. Southern blot analysis of DNA extracted from formalin-fixed pathology specimens. Cancer Res 1986, 46:2964-2969.
22. Zsikla V, Baumann M, Cathomas G. Effect of buffered formalin on amplification of DNA from paraffin wax embedded small biopsies using real-time PCR. J Clin Pathol 2004, 57:654-656. 10.1136/jcp.2003.013961, 1770336, 15166276.
23. Guillou L, Coindre J, Gallagher G, Terrier P, Gebhard S, de Saint Aubain Somerhausen N, Michels J, Jundt G, Vince D, Collin F, et al. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001, 32:105-112. 10.1053/hupa.2001.21130, 11172303.
24. Merkelbach S, Gehlen J, Handt S, Füzesi L. Novel enzyme immunoassay and optimized DNA extraction for the detection of polymerase-chain-reaction-amplified viral DNA form paraffin-embedded tissue. Am J Pathol 1997, 150:1537-1546. 1858222, 9137080.
25. Coates P, d'Ardenne A, Khan G, Kangro H, Slavin G. Simplified procedures for applying the polymerase chain reaction to routinely fixed paraffin wax sections. J Clin Pathol 1991, 44:115-118. 10.1136/jcp.44.2.115, 496971, 1650795.
26. Heinrich MC, Corless CL, Demetri GD, Blancke CD, von Mehren M, Joensuu H, Mc Greevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003, 21:4342-4349. 10.1200/JCO.2003.04.190, 14645423.
27. Hostein I, Longy M, Gastaldello B, Geneste G, Coindre J. Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor. Int J Cancer 2006, 118:2089-2091. 10.1002/ijc.21607, 16287112.
28. Price V, Zielenska M, Chilton-MacNeill S, Smith C, Pappo A. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer 2005, 45:20-24. 10.1002/pbc.20377, 15795882.
29. Do I, Araujo E, Kalil R, Bacchini P, Bertoni F, Unni K, Park Y. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol Res Pract 2007, 203:127-134. 10.1016/j.prp.2006.12.005, 17298867.
30. den Dunnen J, Antonarakis S. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15:7-12. 10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N, 10612815.